# nature portfolio

Corresponding author(s):	Alon Herschhorn
Last updated by author(s):	2023_10_24

## **Reporting Summary**

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our <u>Editorial Policies</u> and the <u>Editorial Policy Checklist</u>.

Sta	atis	tics
For	all st	atistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.
n/a	Cor	nfirmed
	$\boxtimes$	The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
$\boxtimes$		A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
	$\boxtimes$	The statistical test(s) used AND whether they are one- or two-sided  Only common tests should be described solely by name; describe more complex techniques in the Methods section.
	$\boxtimes$	A description of all covariates tested
$\boxtimes$		A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
$\boxtimes$		A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
$\boxtimes$		For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i> ) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted <i>Give P values as exact values whenever suitable.</i>
$\boxtimes$		For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings

Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.

For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes

Estimates of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated

#### Software and code

Policy information about availability of computer code

Data collection

Provide a description of all commercial, open source and custom code used to collect the data in this study, specifying the version used OR state that no software was used.

Data analysis

Graph Pad PRISM version 7 was used to calculate ID50 values. ELIspots were analyzed using the CTL Immunospot analyzer (Immunospot, Cleveland, OH).

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information

#### Data

Policy information about availability of data

All manuscripts must include a <u>data availability statement</u>. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

Data are available in this paper, Supplementary information, or from the corresponding author upon request.

### Research involving human participants, their data, or biological material

Policy information about studies with <u>human participants or human data</u>. See also policy information about <u>sex, gender (identity/presentation)</u>, <u>and sexual orientation</u> and <u>race, ethnicity and racism</u>.

Reporting on sex and gender

Use the terms sex (biological attribute) and gender (shaped by social and cultural circumstances) carefully in order to avoid confusing both terms. Indicate if findings apply to only one sex or gender; describe whether sex and gender were considered in study design; whether sex and/or gender was determined based on self-reporting or assigned and methods used. Provide in the source data disaggregated sex and gender data, where this information has been collected, and if consent has been obtained for sharing of individual-level data; provide overall numbers in this Reporting Summary. Please state if this information has not been collected.

Report sex- and gender-based analyses where performed, justify reasons for lack of sex- and gender-based analysis.

Reporting on race, ethnicity, or other socially relevant groupings

Please specify the socially constructed or socially relevant categorization variable(s) used in your manuscript and explain why they were used. Please note that such variables should not be used as proxies for other socially constructed/relevant variables (for example, race or ethnicity should not be used as a proxy for socioeconomic status).

Provide clear definitions of the relevant terms used, how they were provided (by the participants/respondents, the researchers, or third parties), and the method(s) used to classify people into the different categories (e.g. self-report, census or administrative data, social media data, etc.)

Please provide details about how you controlled for confounding variables in your analyses.

Population characteristics

Describe the covariate-relevant population characteristics of the human research participants (e.g. age, genotypic information, past and current diagnosis and treatment categories). If you filled out the behavioural & social sciences study design questions and have nothing to add here, write "See above."

Recruitment

Describe how participants were recruited. Outline any potential self-selection bias or other biases that may be present and how these are likely to impact results.

Ethics oversight

Identify the organization(s) that approved the study protocol.

Note that full information on the approval of the study protocol must also be provided in the manuscript.

## Field-specific reporting

Please select the one below	that is the best fit for your research	. If you are not sure, read the appropriate sections before making your selection.
🔀 Life sciences	Behavioural & social sciences	Ecological, evolutionary & environmental sciences
For a reference copy of the docume	ent with all sections, see <u>nature.com/document</u>	ts/nr-reporting-summary-flat.pdf

## Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size	Sample size was 2 (rabbits) for preliminary studies and 6 (rabbits) for follow up experiment. Size was determined according to other reported studies and space limitations; no statistical analysis was used to determine sample size.
Data exclusions	Assay was initially optimized using two HIV-1 Envs and optimization data were not included in the report or analysis.
Replication	Experiments were done at least in duplicates
Randomization	Samples were not randomized
Blinding	N/A

## Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

n/a Involved in the study n/a Involved in the study    Antibodies   ChIP-seq			
Antibodies ChIP-seq			
Eukaryotic cell lines			
Palaeontology and archaeology MRI-based neuroimaging			
Animals and other organisms			
Clinical data			
Dual use research of concern			
Plants			
Antibodies			
Antibodies used Anti-HIV-1 Env antibodies provided by the NIH AIDS Reagent Program.			
Validation Antibodies have been previously used in numerous studies and they were not validated further for this study.			
Eukaryotic cell lines			
Policy information about <u>cell lines and Sex and Gender in Research</u>			
Cell line source(s)  NIH Reagent Program; ATCC			
Authentication None of the cell lines were authenticated	None of the cell lines were authenticated		
Mycoplasma contamination Cells were routinely tested for mycoplasma contamination			
Commonly misidentified lines (See ICLAC register)			
Audiental and other encountry and an encountry			
Animals and other research organisms			
Policy information about <u>studies involving animals</u> ; <u>ARRIVE guidelines</u> recommended for reporting animal research, and <u>Sex and Gender in</u> <u>Research</u>			
Laboratory animals New Zealand White rabbits	New Zealand White rabbits		
	None		
Wild animals None			
Reporting on sex  Only female rabbits were used due to the specific focus of the study (vaccine) and the small-size study			

Protocols were reviewed and approved by the Institutional Animal Care and Use Committee (IACUC) of the University of Minnesota.

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Ethics oversight